News

A ‘rapid report’ covering the numerous new and upcoming drugs for hepatitis C – plus new guidelines from WHO and EASL…

The TAILOR study plans to enrol almost 400 HIV positive people who are already on stable HIV treatment. It will use different doses of telmisartan (20 mg, 400 mg and 80 mg) to see whether this reduces the risks of …

CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments…

First reports from CROI 2014: no linked HIV transmissions when viral load is suppressed; 3-monthly PrEP injections, PI/r monotherapy, ACTG 5257, NEAT001, paediatric ARV pipeline, low dose efavirenz and more…

Women and HIV, research update on HIV persistence and cure, sofosbuvir approved for hepatitis C in the US and Europe, priced at $1000 a day…

TB treatment for children, reports from EACS, global funding for treatment, efavirenz and risk of suicide, i-Base job vacancies…

The study that could stop your next HIV test coming back positive…

UK cinema launch of the compelling documentary about the people who fought for the drugs we use today. Meet the director and other activists.

i-Base have a vacancy for a new advocate to join the team. We also are looking at freelance writers to contribute to HIV Treatment Bulletin. Full details.

NOTE: EU granted full approval for elvitegravir on 18 November 2013. ……………… On 19 September 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation in Europe for the integrase inhibitor elvitegravir 85 …

ICAAC and IAS conferences; CROI archive website still blocked; cobicistat approved in the EU, Stribild in England, dolutegravir in the US – and pricing in the UK and globally…

Alternative booster for atazanavir and darunavir approved…

Important decision by NHS England under its new commissioning structure about access to a new HIV drug.

Dolutegravir has disappointingly been priced in the US above existing integrase inhibitors…

Over 20 reports from three leading conferences: 7th IAS conference, 5th Paediatric Workshop and International Drug Resistance Workshop. Plus phasing out d4T, plans for new tenofovir and where is the CROI website?

Expected highlights and early reports from the meeting: WHO guidelines, HIV and children, clinical trials, cure research, treatment strategies and more…

Community reviews on the current state-of-the-art and most exciting clinical research… first comments on WHO 2013 guidelines

Promising new compound should also be developed as separate formulation – please sign on…

Resistance data suggest important clinical benefits for patients with resistance to existing NRTIs including tenofovir.

Coverage of the PK workshop in Amsterdam and further reports from CROI 2103: PMTCT, cardiovascular studies, new HCV drugs and more… plus treatment access including expected new WHO guidelines and Novartis case in India